Literature DB >> 18719371

p53-Ubl fusions as models of ubiquitination, sumoylation and neddylation of p53.

Stephanie Carter1, Karen H Vousden.   

Abstract

The tumour suppressor p53 has been shown to be modified at its C-terminus with ubiquitin and the ubiquitin-like proteins SUMO and NEDD8. Whereas monoubiquitination of p53 is strongly associated with nuclear export, the effects of sumoylation and neddylation remain unclear. In this study we have generated p53-Ub, p53-SUMO-1 and p53-NEDD8 fusion proteins as models for the effect of these modifications on the localization and function of p53. As shown before, the ubiquitin fusion clearly drives nuclear export of p53 and we now find that this is also partially the case for a SUMO-1 fusion, which does not localise to PML bodies. In contrast a NEDD8 fusion has little effect on nuclear export, and mutating NEDD8 to more closely resemble ubiquitin did not restore nuclear export. Despite their differing subcellular localization, we find that both p53-ubiquitin and p53-NEDD8 retain similar transcriptional activity and both induce apoptosis at a similar level to unfused p53. The p53-ubiquitin fusion protein is potentially a good model for studying the role of p53 outside the nucleus. However, in our experiments we find that the export of p53 from the nucleus is not sufficient to activate its cytoplasmic apoptotic function which may depend on the ability to deubiquitinate cytoplasmic p53.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18719371     DOI: 10.4161/cc.7.16.6422

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  29 in total

1.  Differential effects on p53-mediated cell cycle arrest vs. apoptosis by p90.

Authors:  Chao Dai; Yi Tang; Sung Yun Jung; Jun Qin; Stuart A Aaronson; Wei Gu
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-14       Impact factor: 11.205

Review 2.  Posttranslational modification of p53: cooperative integrators of function.

Authors:  David W Meek; Carl W Anderson
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-10-28       Impact factor: 10.005

3.  SUMOylation regulates cytochrome P450 2E1 expression and activity in alcoholic liver disease.

Authors:  Maria Lauda Tomasi; Komal Ramani; Minjung Ryoo; Carla Cossu; Andrea Floris; Ben J Murray; Ainhoa Iglesias-Ara; Ylenia Spissu; Nirmala Mavila
Journal:  FASEB J       Date:  2018-01-18       Impact factor: 5.191

4.  Modification of small hepatitis delta virus antigen by SUMO protein.

Authors:  Chung-Hsin Tseng; Tai-Shan Cheng; Chiung-Yueh Shu; King-Song Jeng; Michael M C Lai
Journal:  J Virol       Date:  2009-11-04       Impact factor: 5.103

Review 5.  Targeting Neddylation pathways to inactivate cullin-RING ligases for anticancer therapy.

Authors:  Yongchao Zhao; Meredith A Morgan; Yi Sun
Journal:  Antioxid Redox Signal       Date:  2014-02-20       Impact factor: 8.401

6.  Integrative genomics analysis identifies candidate drivers at 3q26-29 amplicon in squamous cell carcinoma of the lung.

Authors:  Jing Wang; Jun Qian; Megan D Hoeksema; Yong Zou; Allan V Espinosa; S M Jamshedur Rahman; Bing Zhang; Pierre P Massion
Journal:  Clin Cancer Res       Date:  2013-08-01       Impact factor: 12.531

7.  MDM2 promotes SUMO-2/3 modification of p53 to modulate transcriptional activity.

Authors:  Maren H Stindt; Stephanie Carter; Arnaud M Vigneron; Kevin M Ryan; Karen H Vousden
Journal:  Cell Cycle       Date:  2011-09-15       Impact factor: 4.534

8.  MDA5 is SUMOylated by PIAS2β in the upregulation of type I interferon signaling.

Authors:  Jihuan Fu; Yanbao Xiong; Youli Xu; Genhong Cheng; Hong Tang
Journal:  Mol Immunol       Date:  2010-12-14       Impact factor: 4.407

9.  Overexpression of SKI oncoprotein leads to p53 degradation through regulation of MDM2 protein sumoylation.

Authors:  Boxiao Ding; Yin Sun; Jiaoti Huang
Journal:  J Biol Chem       Date:  2012-03-12       Impact factor: 5.157

Review 10.  Nucleolar control of p53: a cellular Achilles' heel and a target for cancer therapy.

Authors:  Nikolina Vlatković; Mark T Boyd; Carlos P Rubbi
Journal:  Cell Mol Life Sci       Date:  2013-05-18       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.